Evercore ISI analyst Vijay Kumar raised the firm’s price target on Exact Sciences (EXAS) to $70 from $60 and keeps an Outperform rating on the shares. In the firm’s 2025 outlook note for MedTech, Life ...

Barclays raised the firm’s price target on Integral Ad Science (IAS) to $14 from $13 and keeps an Equal Weight rating on the shares. With software “back in favor again,” valuation levels have now ...

Integral Ad Science Holding Corp. IAS will release its financial results for the fourth quarter, before the opening bell, on Friday, Feb. 28, 2025. Analysts expect the New York-based company to report ...

BofA lowered the firm’s price target on Exact Sciences (EXAS) to $72 from $75 and keeps a Buy rating on the shares. The Life Sciences Tools sector underperformed again in FY24 as Pharma and Biotech ...

CAMBRIDGE, Mass., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human ...

Leerink analyst David Risinger raised the firm’s price target on Roivant Sciences (ROIV) to $32 from $29 and keeps an Outperform rating on the shares. The firm cites higher long-term profitability ...

Kodiak Sciences (KOD) has priced an expanded public offering of approximately 6.96 million shares at $23.00 each. The company expects to raise roughly $160 million in gross proceeds. Kodiak Sciences ...

Ten financial analysts have updated their short term price target for Exact Sciences, the company that developed Cologuard, according to an MFI report. The company’s short term price target estimate ...

CAMBRIDGE, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human ...